Decreased insulin secretion and insulin sensitivity are associated with liver function in subjects with fasting glucose between 100 and 109 mg/dL in Taiwanese population

Pancreas

Volumn 35, Issue 4, 2007, Pages 343-347

  Hsiao, Jeng Yueh ^a,b   Wang, Chiao Ling ^a,b   Hsia, Pi Jung ^a   Hsieh, Ming Chia ^a,b   Hsin, Shih Chieh ^a   Lin, Kun Der ^a   Shin, Shyi Jang ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

HOMA B; HOMA IR; IFG; IGT; IR

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIVER ENZYME;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; GLYCEMIC LOAD; HOMEOSTASIS; HUMAN; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TAIWAN;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BLOOD PRESSURE; FASTING; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIPIDS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TAIWAN;

EID: 37349100470     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e31811f44fd     Document Type: Article

References (34)

1. Duckworth WC, Hamel FG, Peavy DE, et al. Hepatic metabolism of insulin. Am J Med. 1998;85:71-76.
2. Michael MD, Kulkarni RN. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6:87-97.
3. Ohlson LO, Larsson B. Risk factors for type 2 diabetes mellitus: thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia. 1988;31:798-805.
4. Perry LJ, Wannamethee SG. Prospective study of serum gamma- glutamyltransferase and risk of NIDDM. Diabetes Care. 1998;21:732-737.
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
6. Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabet Med. 2002;19:708-723.
7. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497.
8. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet. 1999;354:617-621.
9. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
10. Levitan EB, Song Y, Ford ES, et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004;164:2147-2155.
11. Khaw KT, Areham N, Bingham S, et al. Association of hemoglobin A1C with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413-420.
12. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
13. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
14. Wenying Y, Lixiang L, Jimevu Q, et al. The preventative effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Clin J Endocrinol Metab. 2001;17:131-135.
15. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
16. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus. Lancet. 2002;359:2072-2077.
17. Wen CP, Hsu HL. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care. 2005;28:2756-2761.
18. Silverman JF, Pories WJ. Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological and biochemical considerations. Pathol Annu. 1989;24:275-302.
19. Kanaya AM, Herrington D, Vittinghoff E, et al. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med. 2005;142:813-820.
20. Mayer B, Pamela B. Lowering the criterion for impaired fasting glucose will not provide clinical benefit. Diabetes Care. 2003;26:3329-3330.
21. Knowler WC, Barrett-Connor E, The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
22. Pan XR, Lin GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
23. American Diabetes Association. The prevention or delay of type 2 diabetes. Diabetes Care. 2003;26:S62-S66.
24. Yuichi N, Mitsuo F. Insulin secretion and insulin sensitivity in Japanese subjects with impaired fasting glucose and isolated fasting hyperglycemia. Diabetes Res Clin Pract. 2005;70:46-52.
25. Markolf H, Frank S, Carsta K, et al. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2003;26:868-873.
26. Tripathy D, Carlsson M. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49:975-980.
27. Weyer C, Bogardus C. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 1999;48:2197-2203.
28. Hsiao TJ, Chen JC, Wang JD, et al. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord. 2004;28:167-172.
29. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71-79.
30. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889-1895.
31. Ohlson LO, Larsson B, Bjorntorp P, et al. Risk factors for type 2 D.M. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia. 1988;31:798-805.
32. Perry IJ, Wannamethee SG. Prospective study of serum gamma- glutamyltransferase and risk of NIDDM. Diabetes Care. 1998;21:732-737.
33. Emoto M, Nishizawa Y. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999;2:818-822.
34. Garcia-Estevez DA, Araujo-Vilar D. Comparison of several insulin sensitivity indices derived from basal plasma insulin and glucose levels with minimal model indices. Horm Metab Res. 2003;35:13-17.